Anti-tumour therapeutic efficacy of OX40L in murine tumour model
OX40 ligand (OX40L), a member of TNF superfamily, is a co-stimulatory molecule involved in T cell activation. Systemic administration of mOX40L fusion protein significantly inhibited the growth of experimental lung metastasis and subcutaneous (s.c.) established colon (CT26) and breast (4T1) carcinom...
Gespeichert in:
| Veröffentlicht in: | Vaccine 2004-09, Vol.22 (27), p.3585-3594 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 3594 |
|---|---|
| container_issue | 27 |
| container_start_page | 3585 |
| container_title | Vaccine |
| container_volume | 22 |
| creator | Ali, Selman A. Ahmad, Murrium Lynam, June McLean, Cornelia S. Entwisle, Claire Loudon, Peter Choolun, Esther McArdle, Stephanie E.B. Li, Geng Mian, Shahid Rees, Robert C. |
| description | OX40 ligand (OX40L), a member of TNF superfamily, is a co-stimulatory molecule involved in T cell activation. Systemic administration of mOX40L fusion protein significantly inhibited the growth of experimental lung metastasis and subcutaneous (s.c.) established colon (CT26) and breast (4T1) carcinomas. Vaccination with OX40L was significantly enhanced by combination treatment with intra-tumour injection of a disabled infectious single cycle-herpes simplex virus (DISC-HSV) vector encoding murine granulocyte macrophage-colony stimulating factor (mGM-CSF). Tumour rejection in response to OX40L therapy required functional CD4
+ and CD8
+ T cells and correlated with splenocyte cytotoxic T lymphocytes (CTLs) activity against the AH-1 gp70 peptide of the tumour associated antigen expressed by CT26 cells. These results demonstrate the potential role of the OX40L in cancer immunotherapy. |
| doi_str_mv | 10.1016/j.vaccine.2004.03.041 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_66795700</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0264410X04002919</els_id><sourcerecordid>17721522</sourcerecordid><originalsourceid>FETCH-LOGICAL-c530t-eef9932da497973646ca9fcdf45df1fd35c12a14e6009f5690bfb9920fe2d8423</originalsourceid><addsrcrecordid>eNqF0ctq3DAUBmBRWppp2kdoMZSUbuwe3a1VG0IvgYFsUshOaOQjqsGXqWQH8vbRMIZAF81Km-_8OtJPyHsKDQWqvuybe-d9HLFhAKIB3oCgL8iGtprXTNL2JdkAU6IWFO7OyJuc9wAgOTWvyRktp2y53pBvl-Mc63kZpiVV8x9M7oDLHH2FIUTv_EM1hermTsC2imM1LKncWK18mDrs35JXwfUZ363nOfn94_vt1a96e_Pz-upyW3vJYa4RgzGcdU4YbTRXQnlngu-CkF2goePSU-aoQAVgglQGdmFnDIOArGsF4-fk0yn3kKa_C-bZDjF77Hs34rRkq5Q2UgM8C6nWjEp2TPz8fygBdFlVmUI__kP35QPG8t6ipAHZgj4GypPyaco5YbCHFAeXHiwFeyzN7u1amj2WZoHbUlqZ-7CmL7sBu6eptaUCLlbgsnd9SG70MT85BdJo1Rb39eSwFHEfMdnsI44eu5jQz7ab4jOrPAK8gbUt</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1559058072</pqid></control><display><type>article</type><title>Anti-tumour therapeutic efficacy of OX40L in murine tumour model</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><source>ProQuest Central UK/Ireland</source><creator>Ali, Selman A. ; Ahmad, Murrium ; Lynam, June ; McLean, Cornelia S. ; Entwisle, Claire ; Loudon, Peter ; Choolun, Esther ; McArdle, Stephanie E.B. ; Li, Geng ; Mian, Shahid ; Rees, Robert C.</creator><creatorcontrib>Ali, Selman A. ; Ahmad, Murrium ; Lynam, June ; McLean, Cornelia S. ; Entwisle, Claire ; Loudon, Peter ; Choolun, Esther ; McArdle, Stephanie E.B. ; Li, Geng ; Mian, Shahid ; Rees, Robert C.</creatorcontrib><description>OX40 ligand (OX40L), a member of TNF superfamily, is a co-stimulatory molecule involved in T cell activation. Systemic administration of mOX40L fusion protein significantly inhibited the growth of experimental lung metastasis and subcutaneous (s.c.) established colon (CT26) and breast (4T1) carcinomas. Vaccination with OX40L was significantly enhanced by combination treatment with intra-tumour injection of a disabled infectious single cycle-herpes simplex virus (DISC-HSV) vector encoding murine granulocyte macrophage-colony stimulating factor (mGM-CSF). Tumour rejection in response to OX40L therapy required functional CD4
+ and CD8
+ T cells and correlated with splenocyte cytotoxic T lymphocytes (CTLs) activity against the AH-1 gp70 peptide of the tumour associated antigen expressed by CT26 cells. These results demonstrate the potential role of the OX40L in cancer immunotherapy.</description><identifier>ISSN: 0264-410X</identifier><identifier>EISSN: 1873-2518</identifier><identifier>DOI: 10.1016/j.vaccine.2004.03.041</identifier><identifier>PMID: 15315837</identifier><identifier>CODEN: VACCDE</identifier><language>eng</language><publisher>Oxford: Elsevier Ltd</publisher><subject>Animals ; Antineoplastic Agents - administration & dosage ; Antineoplastic Agents - therapeutic use ; Applied microbiology ; Biological and medical sciences ; Cancer ; Cancer Vaccines - therapeutic use ; CD4-Positive T-Lymphocytes - immunology ; CD8-Positive T-Lymphocytes - immunology ; Cell Division - drug effects ; Cell growth ; Cell Line ; Cell Line, Tumor ; CTL ; Cytokines ; Female ; Fundamental and applied biological sciences. Psychology ; Granulocyte-Macrophage Colony-Stimulating Factor - metabolism ; Immunotherapy ; Injections, Intraperitoneal ; Ligands ; Lymphocytes ; Medical sciences ; Membrane Glycoproteins - administration & dosage ; Membrane Glycoproteins - therapeutic use ; Metastasis ; Mice ; Mice, Inbred BALB C ; Microbiology ; Neoplasm Transplantation ; Neoplasms, Experimental - immunology ; Neoplasms, Experimental - therapy ; OX40L ; Peptides ; Proteins ; Rodents ; Simplexvirus - genetics ; Simplexvirus - immunology ; Spleen - cytology ; Spleen - immunology ; T cell receptors ; T-Lymphocytes, Cytotoxic - immunology ; Tumor Necrosis Factors ; Tumors ; Vaccination ; Vaccines ; Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)</subject><ispartof>Vaccine, 2004-09, Vol.22 (27), p.3585-3594</ispartof><rights>2004 Elsevier Ltd</rights><rights>2004 INIST-CNRS</rights><rights>Copyright Elsevier Limited Sep 9, 2004</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c530t-eef9932da497973646ca9fcdf45df1fd35c12a14e6009f5690bfb9920fe2d8423</citedby><cites>FETCH-LOGICAL-c530t-eef9932da497973646ca9fcdf45df1fd35c12a14e6009f5690bfb9920fe2d8423</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/1559058072?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995,64385,64387,64389,72469</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=16059768$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15315837$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ali, Selman A.</creatorcontrib><creatorcontrib>Ahmad, Murrium</creatorcontrib><creatorcontrib>Lynam, June</creatorcontrib><creatorcontrib>McLean, Cornelia S.</creatorcontrib><creatorcontrib>Entwisle, Claire</creatorcontrib><creatorcontrib>Loudon, Peter</creatorcontrib><creatorcontrib>Choolun, Esther</creatorcontrib><creatorcontrib>McArdle, Stephanie E.B.</creatorcontrib><creatorcontrib>Li, Geng</creatorcontrib><creatorcontrib>Mian, Shahid</creatorcontrib><creatorcontrib>Rees, Robert C.</creatorcontrib><title>Anti-tumour therapeutic efficacy of OX40L in murine tumour model</title><title>Vaccine</title><addtitle>Vaccine</addtitle><description>OX40 ligand (OX40L), a member of TNF superfamily, is a co-stimulatory molecule involved in T cell activation. Systemic administration of mOX40L fusion protein significantly inhibited the growth of experimental lung metastasis and subcutaneous (s.c.) established colon (CT26) and breast (4T1) carcinomas. Vaccination with OX40L was significantly enhanced by combination treatment with intra-tumour injection of a disabled infectious single cycle-herpes simplex virus (DISC-HSV) vector encoding murine granulocyte macrophage-colony stimulating factor (mGM-CSF). Tumour rejection in response to OX40L therapy required functional CD4
+ and CD8
+ T cells and correlated with splenocyte cytotoxic T lymphocytes (CTLs) activity against the AH-1 gp70 peptide of the tumour associated antigen expressed by CT26 cells. These results demonstrate the potential role of the OX40L in cancer immunotherapy.</description><subject>Animals</subject><subject>Antineoplastic Agents - administration & dosage</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Applied microbiology</subject><subject>Biological and medical sciences</subject><subject>Cancer</subject><subject>Cancer Vaccines - therapeutic use</subject><subject>CD4-Positive T-Lymphocytes - immunology</subject><subject>CD8-Positive T-Lymphocytes - immunology</subject><subject>Cell Division - drug effects</subject><subject>Cell growth</subject><subject>Cell Line</subject><subject>Cell Line, Tumor</subject><subject>CTL</subject><subject>Cytokines</subject><subject>Female</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Granulocyte-Macrophage Colony-Stimulating Factor - metabolism</subject><subject>Immunotherapy</subject><subject>Injections, Intraperitoneal</subject><subject>Ligands</subject><subject>Lymphocytes</subject><subject>Medical sciences</subject><subject>Membrane Glycoproteins - administration & dosage</subject><subject>Membrane Glycoproteins - therapeutic use</subject><subject>Metastasis</subject><subject>Mice</subject><subject>Mice, Inbred BALB C</subject><subject>Microbiology</subject><subject>Neoplasm Transplantation</subject><subject>Neoplasms, Experimental - immunology</subject><subject>Neoplasms, Experimental - therapy</subject><subject>OX40L</subject><subject>Peptides</subject><subject>Proteins</subject><subject>Rodents</subject><subject>Simplexvirus - genetics</subject><subject>Simplexvirus - immunology</subject><subject>Spleen - cytology</subject><subject>Spleen - immunology</subject><subject>T cell receptors</subject><subject>T-Lymphocytes, Cytotoxic - immunology</subject><subject>Tumor Necrosis Factors</subject><subject>Tumors</subject><subject>Vaccination</subject><subject>Vaccines</subject><subject>Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)</subject><issn>0264-410X</issn><issn>1873-2518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqF0ctq3DAUBmBRWppp2kdoMZSUbuwe3a1VG0IvgYFsUshOaOQjqsGXqWQH8vbRMIZAF81Km-_8OtJPyHsKDQWqvuybe-d9HLFhAKIB3oCgL8iGtprXTNL2JdkAU6IWFO7OyJuc9wAgOTWvyRktp2y53pBvl-Mc63kZpiVV8x9M7oDLHH2FIUTv_EM1hermTsC2imM1LKncWK18mDrs35JXwfUZ363nOfn94_vt1a96e_Pz-upyW3vJYa4RgzGcdU4YbTRXQnlngu-CkF2goePSU-aoQAVgglQGdmFnDIOArGsF4-fk0yn3kKa_C-bZDjF77Hs34rRkq5Q2UgM8C6nWjEp2TPz8fygBdFlVmUI__kP35QPG8t6ipAHZgj4GypPyaco5YbCHFAeXHiwFeyzN7u1amj2WZoHbUlqZ-7CmL7sBu6eptaUCLlbgsnd9SG70MT85BdJo1Rb39eSwFHEfMdnsI44eu5jQz7ab4jOrPAK8gbUt</recordid><startdate>20040909</startdate><enddate>20040909</enddate><creator>Ali, Selman A.</creator><creator>Ahmad, Murrium</creator><creator>Lynam, June</creator><creator>McLean, Cornelia S.</creator><creator>Entwisle, Claire</creator><creator>Loudon, Peter</creator><creator>Choolun, Esther</creator><creator>McArdle, Stephanie E.B.</creator><creator>Li, Geng</creator><creator>Mian, Shahid</creator><creator>Rees, Robert C.</creator><general>Elsevier Ltd</general><general>Elsevier</general><general>Elsevier Limited</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7T2</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20040909</creationdate><title>Anti-tumour therapeutic efficacy of OX40L in murine tumour model</title><author>Ali, Selman A. ; Ahmad, Murrium ; Lynam, June ; McLean, Cornelia S. ; Entwisle, Claire ; Loudon, Peter ; Choolun, Esther ; McArdle, Stephanie E.B. ; Li, Geng ; Mian, Shahid ; Rees, Robert C.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c530t-eef9932da497973646ca9fcdf45df1fd35c12a14e6009f5690bfb9920fe2d8423</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Animals</topic><topic>Antineoplastic Agents - administration & dosage</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Applied microbiology</topic><topic>Biological and medical sciences</topic><topic>Cancer</topic><topic>Cancer Vaccines - therapeutic use</topic><topic>CD4-Positive T-Lymphocytes - immunology</topic><topic>CD8-Positive T-Lymphocytes - immunology</topic><topic>Cell Division - drug effects</topic><topic>Cell growth</topic><topic>Cell Line</topic><topic>Cell Line, Tumor</topic><topic>CTL</topic><topic>Cytokines</topic><topic>Female</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Granulocyte-Macrophage Colony-Stimulating Factor - metabolism</topic><topic>Immunotherapy</topic><topic>Injections, Intraperitoneal</topic><topic>Ligands</topic><topic>Lymphocytes</topic><topic>Medical sciences</topic><topic>Membrane Glycoproteins - administration & dosage</topic><topic>Membrane Glycoproteins - therapeutic use</topic><topic>Metastasis</topic><topic>Mice</topic><topic>Mice, Inbred BALB C</topic><topic>Microbiology</topic><topic>Neoplasm Transplantation</topic><topic>Neoplasms, Experimental - immunology</topic><topic>Neoplasms, Experimental - therapy</topic><topic>OX40L</topic><topic>Peptides</topic><topic>Proteins</topic><topic>Rodents</topic><topic>Simplexvirus - genetics</topic><topic>Simplexvirus - immunology</topic><topic>Spleen - cytology</topic><topic>Spleen - immunology</topic><topic>T cell receptors</topic><topic>T-Lymphocytes, Cytotoxic - immunology</topic><topic>Tumor Necrosis Factors</topic><topic>Tumors</topic><topic>Vaccination</topic><topic>Vaccines</topic><topic>Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ali, Selman A.</creatorcontrib><creatorcontrib>Ahmad, Murrium</creatorcontrib><creatorcontrib>Lynam, June</creatorcontrib><creatorcontrib>McLean, Cornelia S.</creatorcontrib><creatorcontrib>Entwisle, Claire</creatorcontrib><creatorcontrib>Loudon, Peter</creatorcontrib><creatorcontrib>Choolun, Esther</creatorcontrib><creatorcontrib>McArdle, Stephanie E.B.</creatorcontrib><creatorcontrib>Li, Geng</creatorcontrib><creatorcontrib>Mian, Shahid</creatorcontrib><creatorcontrib>Rees, Robert C.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Nursing & Allied Health Database</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Vaccine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ali, Selman A.</au><au>Ahmad, Murrium</au><au>Lynam, June</au><au>McLean, Cornelia S.</au><au>Entwisle, Claire</au><au>Loudon, Peter</au><au>Choolun, Esther</au><au>McArdle, Stephanie E.B.</au><au>Li, Geng</au><au>Mian, Shahid</au><au>Rees, Robert C.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Anti-tumour therapeutic efficacy of OX40L in murine tumour model</atitle><jtitle>Vaccine</jtitle><addtitle>Vaccine</addtitle><date>2004-09-09</date><risdate>2004</risdate><volume>22</volume><issue>27</issue><spage>3585</spage><epage>3594</epage><pages>3585-3594</pages><issn>0264-410X</issn><eissn>1873-2518</eissn><coden>VACCDE</coden><abstract>OX40 ligand (OX40L), a member of TNF superfamily, is a co-stimulatory molecule involved in T cell activation. Systemic administration of mOX40L fusion protein significantly inhibited the growth of experimental lung metastasis and subcutaneous (s.c.) established colon (CT26) and breast (4T1) carcinomas. Vaccination with OX40L was significantly enhanced by combination treatment with intra-tumour injection of a disabled infectious single cycle-herpes simplex virus (DISC-HSV) vector encoding murine granulocyte macrophage-colony stimulating factor (mGM-CSF). Tumour rejection in response to OX40L therapy required functional CD4
+ and CD8
+ T cells and correlated with splenocyte cytotoxic T lymphocytes (CTLs) activity against the AH-1 gp70 peptide of the tumour associated antigen expressed by CT26 cells. These results demonstrate the potential role of the OX40L in cancer immunotherapy.</abstract><cop>Oxford</cop><pub>Elsevier Ltd</pub><pmid>15315837</pmid><doi>10.1016/j.vaccine.2004.03.041</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0264-410X |
| ispartof | Vaccine, 2004-09, Vol.22 (27), p.3585-3594 |
| issn | 0264-410X 1873-2518 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_66795700 |
| source | MEDLINE; ScienceDirect Journals (5 years ago - present); ProQuest Central UK/Ireland |
| subjects | Animals Antineoplastic Agents - administration & dosage Antineoplastic Agents - therapeutic use Applied microbiology Biological and medical sciences Cancer Cancer Vaccines - therapeutic use CD4-Positive T-Lymphocytes - immunology CD8-Positive T-Lymphocytes - immunology Cell Division - drug effects Cell growth Cell Line Cell Line, Tumor CTL Cytokines Female Fundamental and applied biological sciences. Psychology Granulocyte-Macrophage Colony-Stimulating Factor - metabolism Immunotherapy Injections, Intraperitoneal Ligands Lymphocytes Medical sciences Membrane Glycoproteins - administration & dosage Membrane Glycoproteins - therapeutic use Metastasis Mice Mice, Inbred BALB C Microbiology Neoplasm Transplantation Neoplasms, Experimental - immunology Neoplasms, Experimental - therapy OX40L Peptides Proteins Rodents Simplexvirus - genetics Simplexvirus - immunology Spleen - cytology Spleen - immunology T cell receptors T-Lymphocytes, Cytotoxic - immunology Tumor Necrosis Factors Tumors Vaccination Vaccines Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects) |
| title | Anti-tumour therapeutic efficacy of OX40L in murine tumour model |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T12%3A31%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Anti-tumour%20therapeutic%20efficacy%20of%20OX40L%20in%20murine%20tumour%20model&rft.jtitle=Vaccine&rft.au=Ali,%20Selman%20A.&rft.date=2004-09-09&rft.volume=22&rft.issue=27&rft.spage=3585&rft.epage=3594&rft.pages=3585-3594&rft.issn=0264-410X&rft.eissn=1873-2518&rft.coden=VACCDE&rft_id=info:doi/10.1016/j.vaccine.2004.03.041&rft_dat=%3Cproquest_cross%3E17721522%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1559058072&rft_id=info:pmid/15315837&rft_els_id=S0264410X04002919&rfr_iscdi=true |